CCNE1 amplification is synthetic-lethal with PKMYT1 kinase inhibition
D. Gallo, J. T. F. Young, J. Fourtounis, G. Martino, A. Alvarez-Quilon, C. Bernier, N. M. Duffy, R. Papp, A. Roulston, R. Stocco, J. Szychowski, A. Veloso, H. Alam, P. S. Baruah, A. Bonneau Fortin, , D. Durocher
The paper identifies PKMYT1 as a therapeutic target for CCNE1-amplified cancers, showing that its inhibition leads to synthetic lethality and tumor regression in combination with gemcitabine.
bioRxiv · Apr 8, 2021Cancer Biology